Topics

Prexasertib Promising in BRCA Wild-Type Ovarian Cancer

13:32 EST 2 Feb 2018 | OncLive

Prexasertib (LY2606368) induced a 29% response rate with acceptable tolerability in women with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma.

Original Article: Prexasertib Promising in BRCA Wild-Type Ovarian Cancer

NEXT ARTICLE

More From BioPortfolio on "Prexasertib Promising in BRCA Wild-Type Ovarian Cancer"

Quick Search

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...